AltaCorp analyst holds an “Outperform” rating on HEXO with Cannabis 2.0

Shares :

5
(3)

The AltaCorp Capital analyst David Kideckel has issued a report on the 2nd wave of legalization of cannabis that will be in force in a few days is the 17 October 2019

David Kideckel, says that the launch of cannabis derivatives such as edibles, drinks, vapes and topicals marks an inflection point in the development of the Canadian market.


Currently, HEXO is developing various product formats including soft gel capsules, vapes, topicals, edibles, and beverages in order to be well-positioned for when these product categories come online. HEXO’s current products have been well received, winning multiple Canadian Cannabis awards, including 2018 Cannabis Product of the Year and Innovation of the Year with its Elixer CBD peppermint sublingual spray

Kideckel writes.

The analyst estimates that cannabis derivatives will form 24 per cent of HEXO’s total revenue in fiscal 2020 and 34 per cent in fiscal 2021.

He holds an “Outperform” rating on the stock with a target of $10.40

To be updated quickly regarding HEXO and TRUSS sign up for free to our NEWSLETTER.


This article is written and published by The Cannabis Stock


Disclaimer : The Cannabis Stock wants to promote the cannabis market with the best publication on the market. The Cannabis Stock does not recommend selling or buying any of the company mentioned and is not responsible for any losses that may result.

Click on a star to rate this article !

Average rating 5 / 5. Vote count: 3

No votes so far! Be the first to rate this post.


Shares :